A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...

This story mentions weight, weight loss, and/or prescription GLP-1 drugs, which are FDA-approved for weight management in adults diagnosed with obesity or with overweight and at least one ...

In a world where weight loss methods range from trendy diets to prescription medications, a new genetic study offers a fresh perspective. A rare genetic variation has been found to shield individuals ...

A prospective cohort study from the National Health Service (NHS) Diabetes Prevention Program analyzed data from 85,514 participants and found that the month of initiation was a significant predictor ...